EBMT 2018: Investigating breakthrough therapies for treating AML in adults
Therapeutically targeting mutations in myeloma: NF-κB, t(4;14) and BRAF
Why should elderly AML patients take part in clinical trials?
Developments in prognostic factors of acute myeloid leukemia (AML)
Gert J. Ossenkoppele
Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years